Verastem names Michael P. Bailey president and CEO, effective Jan. 1, 2027

VSTM•2026-11-05

Verastem appointed Michael P. Bailey president and CEO, effective Jan. 1, 2027, succeeding Daniel Paterson, who will retire and serve as an adviser.

1. Leadership change

Verastem appointed Michael P. Bailey president and CEO, effective January 1, 2027, succeeding Daniel Paterson. Paterson will retire as president and CEO and serve as an adviser.

Verastem names Michael P. Bailey president and CEO, effective Jan. 1, 2027

1. Leadership change

Related News

Damora Therapeutics grants options for 120,900 shares to five new employees

Baker Hughes director John G. Rice reports acquisition of $531,000 in common shares

Kratos Defense Q3 revenue, adjusted EBITDA beat estimates; raises 2026 EBITDA outlook

Biodesix Q3 revenue misses estimates on seasonality impact, project delays

Nephros Q3 revenue $5.6 million